Effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition in chronic coronary disease: a subanalysis of the LoDoCo2 trial
Authors' conclusion
Pericoronary inflammation did not differ among participants who received low-dose colchicine compared with placebo. Low-dose colchicine was associated with a higher volume of calcified plaque, particularly dense calcified plaque, which is considered a feature of plaque stability.
Study context
- Population
- Patients with chronic coronary disease in LoDoCo2 undergoing CT angiography after median 28.2 months of treatmentLoDoCo2 n=5522
- Participants
- 151 patients
- Comparison
- Low-dose colchicine vs placebo
- Primary endpoint
- Pericoronary adipose tissue (PCAT) attenuation and coronary plaque composition
- Follow-up
- Median treatment duration 28.2 months
Methodological detailscross-sectional, nationwide
- Cross-sectional
- Nationwide
Primary result
As reported in the abstract
Median PCAT attenuation
Colchicine
−79.5
median · Hounsfield units (HU)
Placebo
−78.7
median · HU
P = 0.236
Further findings
Calcified plaque volume · independent of statin therapy
P = 0.041
Dense calcified plaque volume
P = 0.048
Calcified plaque burden
P = 0.035
Low-attenuation plaque burden, by statin intensity (subgroup)
- Lower with colchicine on low-intensity statin, not on high-intensity statin
- pinteraction=0.037
Original publication
Effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition in chronic coronary disease: a subanalysis of the LoDoCo2 trial. Heart. Published 19 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →